

MAY 16, 2017

**INTEGRATED CARE
STRATEGIES TO
ADDRESS THE
IMPACT OF RESIDUAL
SYMPTOMS ON
FUNCTIONAL
OUTCOMES IN MDD**

#MDD2017

6:30PM - 8:30PM | MANDALAY BAY SOUTH CONVENTION CENTER, LAS VEGAS | OCEANSIDE D

www.CMEOutfitters.com/MDD2017

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

Provided by:
**CME
Outfitters** 

INTEGRATED CARE STRATEGIES TO ADDRESS THE IMPACT OF RESIDUAL SYMPTOMS ON FUNCTIONAL OUTCOMES IN MDD



AGENDA

6:00PM – 6:30PM

Registration/Buffer Dinner

6:30PM – 6:35PM

The Voice of the Patient: What Do Residual Symptoms Mean to Them?

6:35PM – 6:55PM

Recognizing the Impact of Residual Symptoms on Disability, Social Functioning, and Workplace Performance

6:55PM – 7:05PM

Case Presentation with Audience Interaction

7:05PM – 7:25PM

Yes, You Have Time: Screening and Monitoring for Residual Symptoms in MDD at Every Visit

7:25PM – 7:35PM

Next Steps: Case Presentation with Audience Interaction

7:35PM – 8:00PM

Treatment Options to Target the Cognitive Symptoms of Depression

8:00PM – 8:30PM

Q&A

TARGET AUDIENCE

PAs managing patients with MDD.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

*For more information about this no fee symposium visit
www.cmeoutfitters.com/MDD2017*



INTEGRATED CARE STRATEGIES TO ADDRESS THE IMPACT OF RESIDUAL SYMPTOMS ON FUNCTIONAL OUTCOMES IN MDD



FACULTY

Roger McIntyre, MD, FRCPC (Moderator)

Professor of Psychiatry and Pharmacology, University of Toronto
Executive Director, Brain and Cognition Discovery Foundation (BCDF)
Head, Mood Disorders Psychopharmacology Unit, University Health Network
Toronto, ON
Canada

Catherine Judd, MS, PA-C, CAQ-Psy, DFAAPA

Clinical Assistant Professor, Department of Physician Assistant Studies
UT Southwestern Medical Center School of Health Professions
Physician Assistant, Mental Health and Behavioral Medicine
Parkland Health and Hospital System
Dallas, TX

Gregory W. Mattingly, MD

Associate Clinical Professor, Washington University School of Medicine
St. Louis, MO
President, Midwest Research Group
St. Charles, MO

LEARNING OBJECTIVES

- Recognize the relationship between residual cognitive symptoms and functional impairment in patients with MDD.
- Assess all of the symptoms of MDD including cognitive and residual symptoms with a validated screening tool at each visit.
- Engage patients in shared decision-making to optimize their treatment options to manage all symptoms of MDD.

ACCREDITATION STATEMENT



AAPA Credit (American Academy of PAs): This program has been reviewed and is approved for a maximum of 2 hours of AAPA Category 1 CME credit by the PA Review Panel. Approval is valid for one year from the issue date of 05/16/2017. Participants may submit the post-test at any time during that period.

This program was planned in accordance with AAPA's CME Standards for Live Programs and for Commercial Support of Live Programs.

INTEGRATED CARE STRATEGIES TO ADDRESS THE IMPACT OF RESIDUAL SYMPTOMS ON FUNCTIONAL OUTCOMES IN MDD



Roger McIntyre, MD, FRCPC (Moderator)

University of Toronto
University Health Network
Toronto, ON
Canada

Biography

Dr. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at

the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.

Dr. McIntyre was named by Thomson Reuters in 2014, as one of "The World's Most Influential Scientific Minds". This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.

Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.

Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.

Dr. McIntyre is the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.

INTEGRATED CARE STRATEGIES TO ADDRESS THE IMPACT OF RESIDUAL SYMPTOMS ON FUNCTIONAL OUTCOMES IN MDD



Catherine Judd, MS, PA-C, CAQ-Psy, DFAAPA

UT Southwestern Medical Center School of Health
Professions
Parkland Health and Hospital System
Dallas, TX

Biography

Ms. Judd, is a Senior PA at Parkland Health and Hospital System, Jail Mental Health Program,


Dallas Texas and Clinical Instructor and Clinical Preceptor at the University of Texas Dallas PA Program. She was among the first to earn the NCCPA CAQ in Psychiatry. She is on the faculty of the CO-REMS content development committee and a national speaker for the APPA Collaborative Risk Management Reduction initiative on prescribing opiates. She has served as a representative from AAPA on the Accreditation Review Commission for PA Programs, and on the NCCPA CAQ Advisory Committee. She has been a key member in the Psychosocial Research Group, Cognitive Behavioral Therapy for Depression and the Psychoneuroendocrinology Research Group in the Department of Psychiatry at UT Southwestern Medical Center. She has published numerous articles on Depression, Bipolar Disorder and Cognitive Impairment. She is a regular speaker at AAPA and other state and national CME conferences.

Her clinical practice over the past 30 years has been primarily mental health and primary care. She has worked internationally in Egypt as well as for a private aid organization in Ghana. She has a special interest in patients with serious mental illness as well as geriatric patients with mood disorders and cognitive decline.

INTEGRATED CARE STRATEGIES TO ADDRESS THE IMPACT OF RESIDUAL SYMPTOMS ON FUNCTIONAL OUTCOMES IN MDD



INTEGRATED CARE STRATEGIES TO ADDRESS THE IMPACT OF RESIDUAL SYMPTOMS ON FUNCTIONAL OUTCOMES IN MDD



Gregory W. Mattingly, MD

Washington University School of Medicine
St. Louis, MO
Midwest Research Group
St. Charles, MO

Biography

Dr. Mattingly is an Associate Clinical Professor and Psychopharmacology Instructor at the Washington University School of Medicine in St. Louis and is also

the President of the Midwest Research Group.

Dr. Mattingly earned his undergraduate degree in chemical engineering and completed his medical degree at the Washington University School of Medicine in St. Louis where he received a Fulbright Scholarship. Board certified in psychiatry with a subspecialty in adolescent psychiatry. Dr. Mattingly serves on the board of directors for APSARD, the American Professional Society for ADHD and Related Disorders. Dr. Mattingly has received numerous awards and distinctions including the Academy of Child and Adolescent Psychiatry National Leadership Award, the Upjohn Neuropsychiatry Research Award, and the Southern Psychiatric Association Research Award.

Dr. Mattingly has been a principal investigator in more than two hundred clinical trials, as well as an invited presenter at numerous medical conferences, both nationally and internationally. Dr. Mattingly's work has been published in *The Journal of Neuropsychiatry and Clinical Neurosciences*, *The Journal of Clinical Psychiatry*, *The Journal of the American Academy of Child and Adolescent Psychiatry*, *Current Psychiatry*, *CNS Spectrums* and *Postgraduate Medicine*.

DISCLOSURE DECLARATION

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. McIntyre reports that he receives research grants from Allergan; AstraZeneca; Janssen Pharmaceuticals Inc.; Lundbeck; Otsuka; Pfizer Inc.; Purdue Pharma; and Shire.

He serves on the advisory board for AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma Corporation; Moksha8 Pharmaceuticals Inc.; Otsuka; Pfizer Inc.; Purdue Pharma; Shire; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.

He receives speaker's fees from AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma Corporation; Moksha8 Pharmaceuticals Inc.; Otsuka; Pfizer Inc.; Purdue Pharma; Shire; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.

Ms. Judd reports that she serves on the speakers bureau for Sunovion Pharmaceuticals Inc. She is a consultant for Sunovion Pharmaceuticals Inc.

Dr. Mattingly reports that he receives research grants from Akili; Alcobra Pharma; Alkermes; Allergan; Boehringer Ingelheim; Forum Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Medgenics, Inc.; NLS-1 Pharma AG; Reckitt Benckiser Group; Shire; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

He serves as a consultant for Alkermes, Allergan, Forum Pharmaceuticals Inc.; Lundbeck; Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Perdue Pharma L.P.; Rhodes Pharmaceuticals L.P.; Shire; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A.; and Vanda Pharmaceuticals.

He receives speaker fee's from Allergan, Lundbeck, Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Shire; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A.; and Vanda Pharmaceuticals.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Sharon Tordoff, CHCP (planning committee) has no disclosures to report.

Jan Perez, CHCP (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

INTEGRATED CARE STRATEGIES TO ADDRESS THE IMPACT OF RESIDUAL SYMPTOMS ON FUNCTIONAL OUTCOMES IN MDD



INSTRUCTIONS FOR INTERACTIVE TECHNOLOGY

If you would like to use your tablet or mobile device to answer polling questions, view the onsite presentations, and submit questions to the faculty, please follow the instructions below:

1. Get Connected

- Please connect to the **CME Outfitters network** with your mobile device or laptop. This network does not have a password.
** Please note that this network is a local network and does NOT mean you're connected to the internet.*
- Once you have joined the network, go to **arraylearn.com**
- You are now connected to the symposium. All content and polling questions can be viewed on your device as long as you are connected to the above listed network.

2. Ask a Question to the Faculty

- Please click on **"Ask a Question"** and type your question. Please include the faculty member's name if the question is specifically for them. Your question will be sent to the faculty for the question and answer portion of the session.

3. View and Take Notes on Presentation Slides

- Please click on the **"Take a Slide Note"** button. If you did not enter your email address when you joined the meeting, you will be required to do so for note taking. When the meeting is complete, all your notes will be emailed to you within 5 business days.

OBTAINING CREDIT

In order to receive credit, please complete the evaluation/credit request forms found on your table and turn them in to the CME Outfitters staff on your way out.

DOWNLOADABLE RESOURCES

Downloadable resources will be available at www.cmeoutfitters.com/MDD2017resources



More Available Activities from CME Outfitters:



Check out a full list of activities on www.neuroscienceCME.com

Cognitive Deficits in Depression

This neuroscienceCME Snack features expert faculty offering new perspectives on treating this pervasive disorder and highlighting cognitive deficits as a challenge to clinicians.

Visit www.neurosciencecme.com/CM21245 to participate.

Mental Health 11: The Class No One Wants to Talk About


In this neuroscienceCME Snack, expert faculty discuss depression among college students and the impact psychiatric disorders have on them personally, as well as their academic progress. The faculty presents resources, campus programs, pharmacological, and nonpharmacological strategies for addressing the problem of depression amongst college students.

Visit www.neurosciencecme.com/CM21243 to participate.

Chair Summit: Master Class for Neuroscience Professional Development Video Replays

Video replays of select plenary sessions available from the 8th and 9th Annual Chair Summit: Master Class in Neuroscience Professional Development.

Visit www.neurosciencecme.com/CHVlist.html to participate.



Celebrate 10 Years of
Chair Summit in New Orleans!

November 16 -18, 2017

Hotel Monteleone
New Orleans, LA

Register today at
www.ChairSummit.com